19-12658134-T-C

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000528.4(MAN2B1):​c.1238A>G​(p.Asn413Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.106 in 1,613,340 control chromosomes in the GnomAD database, including 10,669 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Synonymous variant affecting the same amino acid position (i.e. N413N) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.086 ( 850 hom., cov: 32)
Exomes 𝑓: 0.11 ( 9819 hom. )

Consequence

MAN2B1
NM_000528.4 missense

Scores

4
14

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:10

Conservation

PhyloP100: 2.04

Publications

25 publications found
Variant links:
Genes affected
MAN2B1 (HGNC:6826): (mannosidase alpha class 2B member 1) This gene encodes an enzyme that hydrolyzes terminal, non-reducing alpha-D-mannose residues in alpha-D-mannosides. Its activity is necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover and it is member of family 38 of glycosyl hydrolases. The full length protein is processed in two steps. First, a 49 aa leader sequence is cleaved off and the remainder of the protein is processed into 3 peptides of 70 kDa, 42 kDa (D) and 13/15 kDa (E). Next, the 70 kDa peptide is further processed into three peptides (A, B and C). The A, B and C peptides are disulfide-linked. Defects in this gene have been associated with lysosomal alpha-mannosidosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2010]
MAN2B1 Gene-Disease associations (from GenCC):
  • alpha-mannosidosis
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Genomics England PanelApp, Myriad Women’s Health, G2P, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0019977689).
BP6
Variant 19-12658134-T-C is Benign according to our data. Variant chr19-12658134-T-C is described in ClinVar as Benign. ClinVar VariationId is 129584.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.12 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MAN2B1NM_000528.4 linkc.1238A>G p.Asn413Ser missense_variant Exon 10 of 24 ENST00000456935.7 NP_000519.2 O00754-1
MAN2B1NM_001440570.1 linkc.1241A>G p.Asn414Ser missense_variant Exon 10 of 24 NP_001427499.1
MAN2B1NM_001173498.2 linkc.1235A>G p.Asn412Ser missense_variant Exon 10 of 24 NP_001166969.1 O00754-2A8K6A7
MAN2B1XM_047438841.1 linkc.137A>G p.Asn46Ser missense_variant Exon 3 of 17 XP_047294797.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MAN2B1ENST00000456935.7 linkc.1238A>G p.Asn413Ser missense_variant Exon 10 of 24 1 NM_000528.4 ENSP00000395473.2 O00754-1

Frequencies

GnomAD3 genomes
AF:
0.0865
AC:
13147
AN:
151994
Hom.:
850
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0211
Gnomad AMI
AF:
0.213
Gnomad AMR
AF:
0.0570
Gnomad ASJ
AF:
0.126
Gnomad EAS
AF:
0.000386
Gnomad SAS
AF:
0.0209
Gnomad FIN
AF:
0.205
Gnomad MID
AF:
0.0443
Gnomad NFE
AF:
0.122
Gnomad OTH
AF:
0.0804
GnomAD2 exomes
AF:
0.0901
AC:
22434
AN:
249038
AF XY:
0.0897
show subpopulations
Gnomad AFR exome
AF:
0.0188
Gnomad AMR exome
AF:
0.0440
Gnomad ASJ exome
AF:
0.122
Gnomad EAS exome
AF:
0.000109
Gnomad FIN exome
AF:
0.199
Gnomad NFE exome
AF:
0.123
Gnomad OTH exome
AF:
0.100
GnomAD4 exome
AF:
0.108
AC:
157991
AN:
1461228
Hom.:
9819
Cov.:
34
AF XY:
0.106
AC XY:
77266
AN XY:
726892
show subpopulations
African (AFR)
AF:
0.0167
AC:
560
AN:
33478
American (AMR)
AF:
0.0460
AC:
2056
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.124
AC:
3237
AN:
26136
East Asian (EAS)
AF:
0.0000756
AC:
3
AN:
39698
South Asian (SAS)
AF:
0.0229
AC:
1973
AN:
86256
European-Finnish (FIN)
AF:
0.196
AC:
10384
AN:
52870
Middle Eastern (MID)
AF:
0.0497
AC:
286
AN:
5756
European-Non Finnish (NFE)
AF:
0.120
AC:
133578
AN:
1111928
Other (OTH)
AF:
0.0979
AC:
5914
AN:
60382
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.481
Heterozygous variant carriers
0
8144
16288
24433
32577
40721
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
4646
9292
13938
18584
23230
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0864
AC:
13149
AN:
152112
Hom.:
850
Cov.:
32
AF XY:
0.0875
AC XY:
6502
AN XY:
74336
show subpopulations
African (AFR)
AF:
0.0211
AC:
875
AN:
41524
American (AMR)
AF:
0.0569
AC:
870
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
0.126
AC:
436
AN:
3472
East Asian (EAS)
AF:
0.000387
AC:
2
AN:
5164
South Asian (SAS)
AF:
0.0214
AC:
103
AN:
4820
European-Finnish (FIN)
AF:
0.205
AC:
2169
AN:
10578
Middle Eastern (MID)
AF:
0.0476
AC:
14
AN:
294
European-Non Finnish (NFE)
AF:
0.122
AC:
8319
AN:
67942
Other (OTH)
AF:
0.0791
AC:
167
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
594
1189
1783
2378
2972
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
140
280
420
560
700
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.101
Hom.:
1583
Bravo
AF:
0.0743
TwinsUK
AF:
0.119
AC:
441
ALSPAC
AF:
0.115
AC:
443
ESP6500AA
AF:
0.0200
AC:
88
ESP6500EA
AF:
0.120
AC:
1034
ExAC
AF:
0.0897
AC:
10892
Asia WGS
AF:
0.0150
AC:
54
AN:
3478
EpiCase
AF:
0.109
EpiControl
AF:
0.112

ClinVar

Significance: Benign
Submissions summary: Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Deficiency of alpha-mannosidase Benign:4
Jun 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 22, 2019
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not specified Benign:3
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -

Apr 09, 2014
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
Oct 20, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.092
BayesDel_addAF
Benign
-0.58
T
BayesDel_noAF
Benign
-0.50
CADD
Benign
19
DANN
Uncertain
0.99
DEOGEN2
Benign
0.41
T;.
Eigen
Benign
-0.25
Eigen_PC
Benign
-0.15
FATHMM_MKL
Benign
0.67
D
LIST_S2
Uncertain
0.91
D;D
MetaRNN
Benign
0.0020
T;T
MetaSVM
Benign
-0.95
T
MutationAssessor
Uncertain
2.1
M;.
PhyloP100
2.0
PrimateAI
Benign
0.45
T
PROVEAN
Benign
-2.1
N;N
REVEL
Benign
0.20
Sift
Benign
0.044
D;D
Sift4G
Uncertain
0.028
D;D
Polyphen
0.0050
B;.
Vest4
0.11
MPC
0.48
ClinPred
0.012
T
GERP RS
2.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.068
gMVP
0.51
Mutation Taster
=88/12
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.17
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs35836657; hg19: chr19-12768948; COSMIC: COSV55473709; COSMIC: COSV55473709; API